Skip to main content

Table 3 Mean and standard deviation for primary and secondary outcomes in absolute values (n = 60)

From: What is the optimal time-response window for the use of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) for the improvement of exercise performance and recovery, and for how long the effects last? A randomized, triple-blinded, placebo-controlled trial

Outcomes

Mean (± standard deviation)

Control

(n = 10)

Placebo

(n = 10)

PBMT-sMF

5 mins (n = 10)

PBMT-sMF

3 h (n = 10)

PBMT-sMF

6 h (n = 10)

PBMT-sMF

1-day (n = 10)

MVC

 Baseline

258.2 (±22.3)

269.8 (±25.7)

281.2 (±19.1)

270.1 (±22.4)

269.2 (±22.2)

282.1 (±32.9)

 Immediately after

166.8 (±24.5)

175.4 (±19.6)

239.6 (±41.6) aaaa, bbbb

239.9 (±34.8) aaaa, bbbb

226.7 (±28.1) aaa, bb

234.0 (±35.9) aaaa, bbb

 1 h

164.2 (±28.0)

172.0 (±18.3)

230.1 (±44.6) aaaa, bbb

233.5 (±32.0) aaaa, bbbb

218.5 (±19.6) aaa, bb

223.3 (±39.8) aaa, bb

 24 h

163.1 (±25.5)

175.9 (±21.4)

232.0 (±32.5) aaaa, bbb, ccc

224.2 (±24.9) aaaa, bb, cc

236.9 (±22.8) aaaa, bbbb, ccc

176.6 (±42.2)

 48 h

161.2 (±24.4)

179.6 (±19.2)

252.5 (±45.4) aaaa, bbbb, cccc

231.2 (±22.9) aaaa, bb, cc

242.2 (±14.3) aaaa, bbbb, ccc

183.5 (±41.2)

CK activity

 Baseline

67.2 (±25.7)

65.7 (±23.2)

67.2 (±26.5)

50.9 (±29.9)

63.9 (±35.5)

68.4 (±32.2)

 Immediately after

232.6 (±35.4)

275.7 (±35.8)

90.0 (±31.7) aaaa, bbbb

67.6 (±31.4) aaaa, bbbb

95.0 (±49.9) aaaa, bbbb

90.0 (±44.2) aaaa, bbbb

 1 h

348.8 (±38.5)

391.5 (±47.7)

75.7 (±26.1) aaaa, bbbb

54.9 (±26.8) aaaa, bbbb

86.9 (±51.0) aaaa, bbbb

65.5 (±26.0) aaaa, bbbb

 24 h

519.4 (±55.4)

455.0 (±80.3)

174.8 (±54.4) aaaa, bbbb, cccc

128.0 (±25.5) aaaa, bbbb, cccc

173.4 (±51.5) aaaa, bbbb, cccc

298.7 (±55.7) aaaa, bbbb

 48 h

769.6 (±63.6)

823.6 (±91.5)

181.6 (±64.2) aaaa, bbbb, cccc

138.1 (±96.6) aaaa, bbbb, cccc

161.1 (±65.7) aaaa, bbbb, cccc

693.3 (±72.4) a, bbbb

DOMS intensity

 Baseline

0.0 (±0.0)

0.0 (±0.0)

0.0 (±0.0)

0.0 (±0.0)

0.0 (±0.0)

0.0 (±0.0)

 Immediately after

51.3 (±12.9)

53.9 (±14.2)

15.0 (±9.6) aaaa, bbbb, cccc

16.5 (±12.4) aaaa, bbbb, cccc

18.5 (±10.0) aaaa, bbbb, cccc

42.6 (±15.2)

 1 h

60.5 (±12.4)

65.5 (±13.4)

12.4 (±11.0) aaaa, bbbb, cccc

14.4 (±8.1) aaaa, bbbb, ccc

13.1 (±9.5) aaaa, bbbb, ccc

36.7 (±18.2) aaa, bbbb

 24 h

65.7 (±13.2)

68.4 (±13.3)

21.3 (±9.2) aaaa, bbbb, cccc

16.2 (±7.4) aaaa, bbbb, cccc

17.8 (±14.1) aaaa, bbbb, cccc

46.6 (±23.1) aa, bbb

 48 h

71.4 (±14.2)

76.2 (±15.1)

21.3 (±9.3) aaaa, bbbb, cccc

27.1 (±11.9) aaaa, bbbb, cccc

20.5 (±13.5) aaaa, bbbb, cccc

64.6 (±12.3)

  1. Continuous variables are expressed as mean (±SD)
  2. MVC Maximum Voluntary Contraction (time = p < 0.0001, group = p < 0.0001, interaction = p < 0.0001); CK Creatine Kinase (time = p < 0.0001, group = p < 0.0001, interaction = p < 0.0001); DOMS Delayed Onset Muscle Soreness (time = p < 0.0001, group = p < 0.0001, interaction = p < 0.0001)
  3. a p < 0.05 compared to control, aa p < 0.01 compared to control, aaa p < 0.001 compared to control, aaaa p < 0.0001 compared to control; bb p < 0.01 compared to placebo, bbb p < 0.001 compared to placebo, bbbb p < 0.0001 compared to placebo; cc p < 0.01 compared to PBMT-sMF 1-day, ccc p < 0.001 compared to PBMT-sMF 1-day, cccc p < 0.0001 compared to PBMT-sMF 1-day. Mixed design ANOVA test with Bonferroni post hoc test